{"result": "(\"entity\"<|>ENZIMAS<|>ORGANIZATION<|>Enzymes are biological catalysts that aid in the digestion of food, particularly in patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>LIPASA<|>ORGANIZATION<|>Lipase is an enzyme that helps in the digestion of fats and is crucial for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>AMILASA<|>ORGANIZATION<|>Amylase is an enzyme that aids in the digestion of carbohydrates and is important for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>PROTEASA<|>ORGANIZATION<|>Protease is an enzyme that helps in the digestion of proteins and is essential for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>PACIENTES CON PANCREATITIS CRÓNICA<|>PERSON<|>Patients with chronic pancreatitis often require enzyme supplementation to aid in digestion and absorption of nutrients.)\n##\n(\"relationship\"<|>ENZIMAS<|>FIBROSIS QUÍSTICA<|>Enzymes are necessary for the digestion of food in patients with cystic fibrosis<|>8)\n##\n(\"relationship\"<|>LIPASA<|>FIBROSIS QUÍSTICA<|>Lipase is specifically required for the digestion of fats in patients with cystic fibrosis<|>8)\n##\n(\"relationship\"<|>AMILASA<|>FIBROSIS QUÍSTICA<|>Amylase is required for the digestion of carbohydrates in patients with cystic fibrosis<|>8)\n##\n(\"relationship\"<|>PROTEASA<|>FIBROSIS QUÍSTICA<|>Protease is required for the digestion of proteins in patients with cystic fibrosis<|>8)\n##\n(\"relationship\"<|>PACIENTES CON PANCREATITIS CRÓNICA<|>FIBROSIS QUÍSTICA<|>Patients with chronic pancreatitis may have similar digestive enzyme needs as those with cystic fibrosis<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: esta con las formulaciones del mercado. Las enzimas están recubiertas por una cubierta entérica que se disuelve en medio básico. Por tanto, no se pueden mezclar con productos alimenticios con pH básico (lácteos o antiácidos) y tampoco masticar o machacar. No existe un consenso claro sobre cuál es el mejor momento de administración. En general, se recomienda tomar antes de las comidas y, en el caso de ser muchas, antes y durante las mismas. No obstante, se ha publicado, en pacientes con pancreatitis crónica, que la absorción podría ser mejor si se toman justo después de las comidas o bien repartidas antes (1/4), durante (1/2) y después (1/4). En cualquier caso, si no se alcanzan los objetivos de absorción, debe probarse modificar el momento de administración. Las enzimas realizan su máximo efecto hasta los 30 minutos de ser ingeridas.\n\nDeberán administrarse con las comidas que contengan grasa (prácticamente todas, salvo las que solo necesitan las enzimas del borde en cepillo de la mucosa intestinal para su digestión como frutas, zumos de frutas, ciertas verduras, etc.). La dosis será individualizada y flexible en relación con la ingesta y, en todo caso, se intentará alcanzar la mínima dosificación que sea eficaz. En niños y adultos se suelen aportar entre 500 y 4.000 UI de lipasa por gramo de grasa. Es, por tanto, muy importante adiestrar a los pacientes y familiares en el contenido de grasa de los alimentos. Se puede comenzar por la mínima dosis recomendada (500 UI de lipasa/g de grasa) e ir subiendo progresivamente. No se debe sobrepasar la dosis de 10.000 UI de lipasa/kg de peso/día o las 2.500 unidades de lipasa/kg/ dosis76.\n\nLas dosis de enzimas deben ajustarse según la clínica (dolor cólico, peso, crecimiento), la frecuencia y las características organolépticas de las heces (textura, color, olor). No obstante, ni la clínica ni la frecuencia de las deposiciones correlaciona bien con la dosis de enzimas ni con el grado de malabsorción, por lo que la determinación de grasa en heces (mejor de 3 días), junto con la encuesta dietética, permite calcular con mayor precisión el porcentaje de absorción de grasa de la dieta. Si la absorción de grasa es inadecuada y no se detectan problemas en relación con la distribución, administración o almacenamiento de las enzimas o en la adherencia al tratamiento, se puede intentar mejorar disminuyendo el pH gastrointestinal mediante la administración de inhibidores de la bomba de protones o anti-H2. Las preparaciones disponibles en España se detallan en la tabla 9. Están en investigación nuevas formulaciones que mejoren su eficacia y cumplimiento. Así, se están probado lipasas de origen diferente al porcino (como la liprotamasa) o se han incluido moléculas de bicarbonato en la formulación77.\n---\nTema 35. Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar... 569\n\nTabla 9. Preparados de enzimas pancreáticas (microencapsuladas) existentes en España y recomendaciones de uso en la fibrosis quística.\n\n| Enzimas | Kreon 10000® | Kreon 25000® | Kreon 5000 granulado® |\n|---------|--------------|--------------|------------------------|\n| Lipasa | 10000 U | 25000 U | 50000 U/g<br>Una cucharada = 5.000 U |\n| Amilasa (alfa) | 8000 U | 18000 U | 36000 U/g<br>Una cucharada = 3.600 U |\n| Proteasa | 600 U | 1000 U | 2000 U/g<br>Una cucharada = 200 U |\n| Presentación | Envases de 100 y 250 cápsulas | Envases de 50 y 100 cápsulas | Solución para suspensión 20 g |\n\nRecomendaciones de empleo en FQ:\n- No mezclar con productos alimenticios con pH básico (lácteos) o antiácidos.\n- No masticar o machacar.\n- Suelen administrarse antes de las comidas y, en el caso de ser muchas, antes (2/3) y durante las mismas (1/3 restante). También es adecuado tomarlo justo después de las comidas o repartidos antes (1/4) durante (1/2) y tras las mismas (1/4).\n- En lactantes o niños pequeños abrir las cápsulas y mezclarlas con agua o bebidas ligeramente ácidas (zumos o pulpa de fruta) en una cucharadita.\n- Las enzimas deberán administrarse con las comidas que contengan grasa.\n- La dosis será individualizada entre 500 y 4.000 UI de lipasa por gramo de grasa comenzando por la mínima dosis recomendada e ir sub\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>KREON 10000<|>ORGANIZATION<|>Kreon 10000 is a pancreatic enzyme preparation available in Spain, containing 10,000 units of lipase per dose, used for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>KREON 25000<|>ORGANIZATION<|>Kreon 25000 is a pancreatic enzyme preparation available in Spain, containing 25,000 units of lipase per dose, used for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>KREON 5000 GRANULADO<|>ORGANIZATION<|>Kreon 5000 granulado is a pancreatic enzyme preparation available in Spain, containing 5,000 units of lipase per gram, used for patients with pancreatic insufficiency.)\n##\n(\"entity\"<|>FIBROSIS QUÍSTICA<|>EVENT<|>Cystic fibrosis is a genetic disorder that affects the lungs and digestive system, requiring enzyme supplementation for proper digestion.)\n##\n(\"entity\"<|>ESPANA<|>GEO<|>Spain is the country where the pancreatic enzyme preparations are available and recommended for use in patients with cystic fibrosis.)\n##\n(\"relationship\"<|>KREON 10000<|>FIBROSIS QUÍSTICA<|>Kreon 10000 is recommended for use in patients with cystic fibrosis to aid in digestion<|>8)\n##\n(\"relationship\"<|>KREON 25000<|>FIBROSIS QUÍSTICA<|>Kreon 25000 is recommended for use in patients with cystic fibrosis to aid in digestion<|>8)\n##\n(\"relationship\"<|>KREON 5000 GRANULADO<|>FIBROSIS QUÍSTICA<|>Kreon 5000 granulado is recommended for use in patients with cystic fibrosis to aid in digestion<|>8)\n##\n(\"relationship\"<|>KREON 10000<|>ESPANA<|>Kreon 10000 is available in Spain for patients requiring pancreatic enzyme supplementation<|>7)\n##\n(\"relationship\"<|>KREON 25000<|>ESPANA<|>Kreon 25000 is available in Spain for patients requiring pancreatic enzyme supplementation<|>7)\n##\n(\"relationship\"<|>KREON 5000 GRANULADO<|>ESPANA<|>Kreon 5000 granulado is available in Spain for patients requiring pancreatic enzyme supplementation<|>7)\n<|COMPLETE|>"}]}